Arrowhead Research Corp (ARWR) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $-0.32 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.04. Analysts had a consensus of $-0.36. The company posted revenue of $39.58 million in the period, compared to analysts expectations of $.05 million. The company’s revenue was down -68.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.
Many Wall Street Analysts have commented on Arrowhead Research Corp. Chardan Capital Markets Initiated Arrowhead Research Corp on May 19, 2016 to “Buy”, Price Target of the shares are set at $12.
Arrowhead Research Corp closed down -0.09 points or -1.50% at $5.9 with 2,82,060 shares getting traded on Monday. Post opening the session at $6.01, the shares hit an intraday low of $5.78 and an intraday high of $6.0656 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jan 4, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 23,347 shares at $6.13 per share price. According to the SEC, on Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price. On Jan 7, 2015, David L. Lewis (Chief Scientific Officer) sold 15,000 shares at $8.01 per share price, according to the Form-4 filing with the securities and exchange commission.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.